Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company’s lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Pivotal Gene Therapy | Tenaya Therapeutics approaches critical milestones in cardiac gene therapy development, with key clinical trial data expected in late 2024 |
AAV9 Vector Promise | Explore Tenaya's innovative use of AAV9 delivery vector, showing superior performance across species and potential for enhanced efficacy in humans |
Market Positioning | Delve into Tenaya's strategic focus on MYBPC3-related hypertrophic cardiomyopathy, addressing a significant unmet need in cardiac genetic disorders |
Financial Outlook | Analyst price target of $40 highlights potential upside, with stock performance closely tied to upcoming clinical trial outcomes and cash management |
Metrics to compare | TNYA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTNYAPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −4.0x | −0.5x | |
PEG Ratio | −0.03 | 0.00 | 0.00 | |
Price/Book | 0.8x | 2.1x | 2.6x | |
Price / LTM Sales | - | 37.0x | 2.9x | |
Upside (Analyst Target) | - | 198.6% | 64.0% | |
Fair Value Upside | Unlock | 3.6% | 9.4% | Unlock |